-
KN026 Second-line treatment of HER2-expressing gastric cancer or gastroesophageal junction cancer results published in the internationally renowned journal EJC Press Release
Time of Update: 2023-01-05
Suzhou, China, November 23, 2022 – Corning Jerry Biopharmaceuticals (stock code: 9966. HK) and CSPC Pharmaceutical Group (stock code: 1093. HK) HK) jointly announced that the results of the phase II.
-
ADC drugs targeting mucin tumor-specific glycotopes
Time of Update: 2023-01-05
ADCs targeting other mucin glycotopesA highly tumor-specific rabbit/human chimeric IgG1 mAb, named PODO447, was recently developed, which binds to Podxl expressed on tumor cells rather than on normal tissue.
-
A major breakthrough in 27 years! Immunotherapy brings the dawn of "new cancer king" treatment!
Time of Update: 2023-01-05
Analytical data showed that patients with newly diagnosed glioblastoma treated with DCVax-L had a relative 20% lower risk of death at any time point, and this relative survival benefit increased over time: 48 months after randomization, DCVax-L and external controls, respectively 15.
-
Non-gene edited 6-antigen-targeted T cell therapy was approved for IND as a first-line treatment for solid tumors
Time of Update: 2023-01-05
November 24, 2022 /eMedClub News/-- Marker Therapeutics, a T-cell immunotherapy development company focused on the development of indications for the treatment of hematologic malignancies and solid tu
-
2022 CSCO Professor Li Ning: The urgent need for new drugs drives new options for the treatment of platinum-resistant recurrent ovarian cancer
Time of Update: 2023-01-05
What will be the boon for patients with platinum-resistant recurrent ovarian cancer?Professor Li NingCancer Hospital, Chinese Academy of Medical SciencesIN10018 is a highly selective plaquekinase (FAK) inhibitor independently developed in China.
-
Science Advances China Pharmaceutical University Sun Agile / Zhejiang University Gu Zhen develops novel protein delivery methods to enhance cancer immunotherapy
Time of Update: 2023-01-05
This study uses CD8+ T cells to form pores in the plasma membrane of tumor cells, perfuse ribonuclease A (RNase A) and granzyme B into the cells, thereby effectively inducing apoptosis and pyroptosis by activating the caspase 3 and gasdermin E pathways, and enhancing CD8+ T cell-mediated immunotherapy.
-
Measurable residual disease: predictor of mantle cell lymphoma outcome
Time of Update: 2023-01-05
Residual disease (MRD) status that can be measured after treatment in peripheral blood and bone marrow correlates with clinical outcomes in patients with B-cell lymphoma.
Residual disease (MRD) status that can be measured after treatment in peripheral blood and bone marrow correlates with clinical outcomes in patients with B-cell lymphoma.
-
【Lancet】Auxiliary diagnosis of new models! Chinese Academy of Medical Sciences detects gene mutations and methylation changes in bile to diagnose pancreatobiliary cancer!
Time of Update: 2023-01-05
Patients with pancreatobiliary tract cancer generally have a poor clinical prognosis, with a 5-year overall survival rate of less than 20%. This is mainly related to late diagnosis. Accurate preoperat
-
【Nature Sub-issue】Breakthrough! Stanford University study: radiotherapy combined with CD47 blocks the potential mechanism of anti-tumor!
Time of Update: 2023-01-05
(Click above to view the detailed schedule)This article is the original of Translational Medicine Network, please indicate the source for reprintingWritten by SophiaAlthough targeted therapies for multiple cancer types have been successfully developed, radiation therapy remains the backbone of cancer treatment, with more than 50% of cancer patients receiving radiation therapy during treatment.
-
Eur Urol Focus: How do tissue changes relate to treatment outcomes during the treatment of prostate cancer with high-intensity focused ultrasound lesions?
Time of Update: 2023-01-05
Recently, researchers from the United States published an article in Eur Urol Focus to evaluate the relationship between intraoperative TCM and oncological outcomes after 12 months during focused HIFU therapy for localized prostate cancer.
-
Research Frontier The second-line immune combination regimen for the treatment of advanced kidney cancer is worth paying attention to——nivolumab + ipilimumab
Time of Update: 2023-01-05
GuideImmuno-oncology (IO) therapies, which include immune checkpoint inhibitor (ICI) monotherapy and combination therapy, have become the standard of care for first- and second-line treatment for pati
-
30-year follow-up data: Can early-stage breast cancer be treated without chemotherapy?
Time of Update: 2023-01-05
For early-stage breast cancer, breast-conserving surgery is usually treated with radiation therapy with chemotherapy or tamoxifen to reduce the risk of recurrence. But how long can this risk-reducing
-
The clinical benefit rate is 38%, and the latest data on PROTAC therapy are available
Time of Update: 2023-01-05
▲If you have any business needs, please press and hold to scan the QR code above, or▎WuXi AppTec content team editorArvinas today disclosed the results of its trial of its innovative PROTAC protein degrader, ARV-471, showing a clinical benefit rate (CBR) of 38% observed in the patient population receiving pre-median 4-line therapy.
-
2022 CSCO |Professor Wu Lingying: Promoting the Standardized Diagnosis and Treatment of Ovarian Cancer and Helping "Healthy China 2030"
Time of Update: 2023-01-05
Could you please bring some messages to young and middle-aged gynecological oncologists to help the diagnosis and treatment of gynecological oncology in China to the forefront of the world?Professor Wu LingyingCancer Hospital, Chinese Academy of Medical SciencesIn recent years, many good achievements have been made in the field of gynecological oncology, and have gradually been recognized by international peers.
-
This kind of "almost incurable" brain cancer, but scientists have found new targets for treatment!
Time of Update: 2023-01-05
The study found:A specific protein called ubiquitin-specific protease 16 (USP16) regulates aging and attenuates the growth of glioma cells;A separate strip of long noncoding RNA—a molecule that controls gene activity—called lncEPAT, was also identified, activated by EGFR and highly functional in GBM.
-
Professor Lv Jing | Stomach Lai Xianfeng (9): In-depth analysis of CheckMate-649 Chinese subgroup data and the differences between Chinese and global data
Time of Update: 2023-01-05
In August 2021, based on the results of CheckMate-649 research, nivolumab (trade name: Odivor) ® became the first PD-1 inhibitor approved in China for the first-line treatment of advanced gastric canc
-
Eur Urol: How effective is retroperitoneal lymph node dissection in patients with clinical stage IIA/B testicular germ cell tumors?
Time of Update: 2023-01-05
Retroperitoneal lymph node dissection (RPLND) for clinically staged (CS) stage IIA/B seminoma is an experimental treatment with no adjuvant therapy to avoid radiotherapy or chemotherapy-related toxicity with standard treatments.
-
【Wednesday Literature Reading】Professor Jia Yujiao| Big Coffee Commentary: Perfection, from the 2022 BSH acute myeloid leukemia laboratory testing practice recommendations to see the latest progress of ASH
Time of Update: 2023-01-05
The diagnosis of AML involves combining the patient's clinical presentation with laboratory tests such as morphology, immunology, cytogenetics, and molecular biology assessment (MICM) of peripheral blood and bone marrow cells.
-
The "All Cases" Lung Cancer Diagnosis and Treatment Practice Sharing Project was staged in the divisional final, directly hitting the forefront of SCLC immunotherapy!
Time of Update: 2023-01-05
*For medical professionals onlyLeaders in the field gathered together to share classic lung cancer diagnosis and treatment cases and discuss the way of lung cancer immunotherapy!Lung cancer is the fir
-
2022 CSCO | Professor Wang Tao: Explore and forge ahead, and help patients with breast cancer brain metastases live longer and better lives
Time of Update: 2023-01-05
prefaceThe 25th National Congress of Clinical Oncology and the 2022 CSCO Annual Conference were held from November 5th to 12th. The conference focuses on the clinical frontier of oncology, invites wel
